JP7900637B2 - 抗菌剤及び抗癌剤 - Google Patents

抗菌剤及び抗癌剤

Info

Publication number
JP7900637B2
JP7900637B2 JP2023565466A JP2023565466A JP7900637B2 JP 7900637 B2 JP7900637 B2 JP 7900637B2 JP 2023565466 A JP2023565466 A JP 2023565466A JP 2023565466 A JP2023565466 A JP 2023565466A JP 7900637 B2 JP7900637 B2 JP 7900637B2
Authority
JP
Japan
Prior art keywords
cancer
compounds
compound
pharmaceutical composition
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023565466A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515215A5 (cg-RX-API-DMAC7.html
JP2024515215A (ja
Inventor
ミュラー、トーマス
メーラー、ハンス
コスティン、ジェイムズ・シー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Persevere Therapeutics Inc
Original Assignee
Persevere Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Persevere Therapeutics Inc filed Critical Persevere Therapeutics Inc
Publication of JP2024515215A publication Critical patent/JP2024515215A/ja
Publication of JP2024515215A5 publication Critical patent/JP2024515215A5/ja
Application granted granted Critical
Publication of JP7900637B2 publication Critical patent/JP7900637B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
    • C07D291/06—Six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023565466A 2021-04-29 2022-04-28 抗菌剤及び抗癌剤 Active JP7900637B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163181492P 2021-04-29 2021-04-29
US63/181,492 2021-04-29
PCT/IB2022/053973 WO2022229907A1 (en) 2021-04-29 2022-04-28 Antimicrobial and anticancer agents

Publications (3)

Publication Number Publication Date
JP2024515215A JP2024515215A (ja) 2024-04-05
JP2024515215A5 JP2024515215A5 (cg-RX-API-DMAC7.html) 2025-04-30
JP7900637B2 true JP7900637B2 (ja) 2026-08-05

Family

ID=81598080

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023565466A Active JP7900637B2 (ja) 2021-04-29 2022-04-28 抗菌剤及び抗癌剤

Country Status (9)

Country Link
US (1) US12612375B2 (cg-RX-API-DMAC7.html)
EP (1) EP4330238A1 (cg-RX-API-DMAC7.html)
JP (1) JP7900637B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240004303A (cg-RX-API-DMAC7.html)
CN (1) CN117295720A (cg-RX-API-DMAC7.html)
AU (1) AU2022267897A1 (cg-RX-API-DMAC7.html)
CA (1) CA3216783A1 (cg-RX-API-DMAC7.html)
IL (1) IL307990A (cg-RX-API-DMAC7.html)
WO (1) WO2022229907A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024177036A1 (ja) * 2023-02-20 2024-08-29 大鵬薬品工業株式会社 Ftd・tpi配合剤、pd-1経路アンタゴニスト、及びvegf経路アンタゴニストの併用
WO2026074499A1 (en) * 2024-10-03 2026-04-09 Geistlich Pharma Ag Methods and compositions for inhibiting c-myc

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150182534A1 (en) 2012-06-18 2015-07-02 Geistlich Pharma Ag Oxathiazine derivatives as antibacterial and anticancer agents
JP2018502909A (ja) 2014-12-19 2018-02-01 ガイストリッヒ・ファルマ・アーゲーGeistlich Pharma Ag オキサチアジン様化合物を作製する方法
WO2020234828A1 (en) 2019-05-22 2020-11-26 Geistlich Pharma Ag Oxathiazin compounds for inhibiting gapdh

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1160443B (de) 1961-11-30 1964-01-02 Hoechst Ag Verfahren zur Herstellung von Tetrahydro-oxathiazin-dioxyden
GB8617482D0 (en) 1986-07-17 1986-08-28 Geistlich Soehne Ag Pharmaceutical composition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150182534A1 (en) 2012-06-18 2015-07-02 Geistlich Pharma Ag Oxathiazine derivatives as antibacterial and anticancer agents
JP2018502909A (ja) 2014-12-19 2018-02-01 ガイストリッヒ・ファルマ・アーゲーGeistlich Pharma Ag オキサチアジン様化合物を作製する方法
WO2020234828A1 (en) 2019-05-22 2020-11-26 Geistlich Pharma Ag Oxathiazin compounds for inhibiting gapdh

Also Published As

Publication number Publication date
IL307990A (en) 2023-12-01
EP4330238A1 (en) 2024-03-06
KR20240004303A (ko) 2024-01-11
US12612375B2 (en) 2026-04-28
CA3216783A1 (en) 2022-11-03
CN117295720A (zh) 2023-12-26
WO2022229907A1 (en) 2022-11-03
US20240199563A1 (en) 2024-06-20
AU2022267897A1 (en) 2023-11-02
JP2024515215A (ja) 2024-04-05

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250421

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260507

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20260604

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260604